Lev Pharmaceuticals licenses IVIG technology for treatment of immune system disorders

By Lisa Kerner

Erie, Pa., May 24 - Lev Pharmaceuticals, Inc. has entered into an exclusive license agreement with Hannu Suomela of Finland related to methods for producing plasma-derived intravenous immunoglobulin (IVIG) used to treat immune system disorders including chronic lymphocytic leukemia and HIV.

Suomela is the inventor of and holds the pending U.S. patent application for the underlying technology.

"We see IVIG as a product opportunity addressing multiple medical needs in a significant patient population," chief executive officer Joshua D. Schein said in a company news release.

"This agreement reflects our strategy of broadening our technology platform and expanding our pipeline with related products that are complementary to our existing technology platform and scientific expertise."

Immune system disorders, encompassing more than 100 diseases, affect as many as 50,000 people in the United States.

Lev, a New York biopharmaceutical company, develops therapeutic products for the treatment of inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.